Xiaohua Zhou
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Xiaohua Zhou has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Hongjian Ji
Yancheng City Therapeutic Drug Precision Testing Engineering Center, School of Pharmacy, Jiangsu Medical College, China
9 shared publications Jianxiang Song
Department of Pharmacy, Department of Nephrology, The Sixth Affiliated Hospital of Nantong, Yancheng
2 shared publicationsQinfang Tang
Microbiology Department, Affiliated Hospital 6 of Nantong University, Yancheng Third People’s Hospital, Yancheng City, China
2 shared publicationsYu Shi
Department of Pharmacy, Affiliated Nantong Hospital 3 of Nantong University, Nantong Third People’s Hospital, Nantong City, China
2 shared publicationsCheng Guo
Department of Pharmacy, Jiangsu Vocational College of Medicine, Jiangsu, People's Republic of China
1 shared publication- Dean Guo
School of Chinese Materia Medica, Nanjing University of Chinese Medicine, Xianlin Road #138, Nanjing
1 shared publication
Latest Publications
- Open Access
- 12 May 2026
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 26 (1)
Clostridium paraputrificum-induced necrotizing enteritis and bacteremia: a rare case report and review of the literature
Colon carcinoma is a prevalent gastrointestinal malignancy, representing a significant public health burden, necessitating integrated surgical and oncologi
- 12 May 2026
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 26 (1)
Open AccessClostridium paraputrificum-induced necrotizing enteritis and bacteremia: a rare case report and review of the literature
Colon carcinoma is a prevalent gastrointestinal malignancy, representing a significant public health burden, necessitating integrated surgical and oncologi
- 30 July 2024
- Published by BMJ in European Journal of Hospital Pharmacy
- Vol. 33 (2) , 195.2-195
Appropriate therapeutic drug monitoring of vancomycin improves outcomes of patients with bacterial infection in ICU
- 30 July 2024
- Published by BMJ in European Journal of Hospital Pharmacy
- Vol. 33 (2) , 195.2-195
Appropriate therapeutic drug monitoring of vancomycin improves outcomes of patients with bacterial infection in ICU
- 3 February 2023
- Published by BMJ in European Journal of Hospital Pharmacy
- Vol. 31 (2) , 178-179
Correspondence on ‘Management of nirmatrelvir/ritonavir and tacrolimus interaction in kidney transplant recipients infected by COVID-19: a three-case series’
- 3 February 2023
- Published by BMJ in European Journal of Hospital Pharmacy
- Vol. 31 (2) , 178-179
Correspondence on ‘Management of nirmatrelvir/ritonavir and tacrolimus interaction in kidney transplant recipients infected by COVID-19: a three-case series’
- 9 June 2022
- Published by BMJ in European Journal of Hospital Pharmacy
- Vol. 30 (4) , e21
A risk prediction model of linezolid-induced thrombocytopenia for elderly patients with chronic kidney disease is urgently needed
- 9 June 2022
- Published by BMJ in European Journal of Hospital Pharmacy
- Vol. 30 (4) , e21
A risk prediction model of linezolid-induced thrombocytopenia for elderly patients with chronic kidney disease is urgently needed
- Open Access
- 9 July 2021
- Published by Wolters Kluwer Health in Medicine
- Vol. 100 (27) , e26510
Aristolochic acid nephropathy
Background: Aristolochic acid nephropathy (AAN) is a type of drug-induced nephropathy that may result in acute kidney injury and is associated with a potentially progressive course of kidney fibrosis and upper tract urothelial carcinoma. Aristolochic acids (AAs) are a group of toxins commonly present in plants of the genera Aristolochia and Asarum, which are found worldwide. AAN still occurs in Asian and Balkan regions. The progressive lesions and mutational events initiated by AAs are irreversible, and no effective therapeutic regimen for AAN has been established. Furthermore, more people are at risk of this disease due to casual exposure to AAs. This study performed a scientometric analysis of global research literature focusing on AAN. Methods: The Web of Science database was searched to identify all publications pertaining to “aristolochic acid nephropathy” or “Balkan endemic nephropathy” using these terms as key words to search the literature from 1971 to 2019. The collected data included the document type, author, journal, publication year, citation reports, and country of publication, and were analyzed using the VOSviewer software. Results: A total of 1251 records were initially obtained. Publication types, including “meeting abstract,” “letter,” “editorial material,” and “proceedings paper” were excluded, which left 1083 publications comprising 923 articles and 160 reviews. English was the predominant language of the publications. China had the most number of articles published with 217 (20.0%), followed by the USA with 186 articles (17.2%), and Germany with 138 articles (12.7%). Kidney International, Food and Chemical Toxicology, and Toxins were the 3 most active journals in publishing articles related to AAN. The total number of citations received by all publications was 39,970, with an average of 36.91 citations per article (range: 0–1769). The literature mainly focused on apoptosis, oxidative stress, and inflammation in AAN. Conclusion: This study indicated that AAN is a significant topic in nephrology research, as shown by the large number of publications. The literature has mainly focused on the mechanisms of AA-induced nephropathy.
- 9 July 2021
- Published by Wolters Kluwer Health in Medicine
- Vol. 100 (27) , e26510
Open AccessAristolochic acid nephropathy
Background: Aristolochic acid nephropathy (AAN) is a type of drug-induced nephropathy that may result in acute kidney injury and is associated with a potentially progressive course of kidney fibrosis and upper tract urothelial carcinoma. Aristolochic acids (AAs) are a group of toxins commonly present in plants of the genera Aristolochia and Asarum, which are found worldwide. AAN still occurs in Asian and Balkan regions. The progressive lesions and mutational events initiated by AAs are irreversible, and no effective therapeutic regimen for AAN has been established. Furthermore, more people are at risk of this disease due to casual exposure to AAs. This study performed a scientometric analysis of global research literature focusing on AAN. Methods: The Web of Science database was searched to identify all publications pertaining to “aristolochic acid nephropathy” or “Balkan endemic nephropathy” using these terms as key words to search the literature from 1971 to 2019. The collected data included the document type, author, journal, publication year, citation reports, and country of publication, and were analyzed using the VOSviewer software. Results: A total of 1251 records were initially obtained. Publication types, including “meeting abstract,” “letter,” “editorial material,” and “proceedings paper” were excluded, which left 1083 publications comprising 923 articles and 160 reviews. English was the predominant language of the publications. China had the most number of articles published with 217 (20.0%), followed by the USA with 186 articles (17.2%), and Germany with 138 articles (12.7%). Kidney International, Food and Chemical Toxicology, and Toxins were the 3 most active journals in publishing articles related to AAN. The total number of citations received by all publications was 39,970, with an average of 36.91 citations per article (range: 0–1769). The literature mainly focused on apoptosis, oxidative stress, and inflammation in AAN. Conclusion: This study indicated that AAN is a significant topic in nephrology research, as shown by the large number of publications. The literature has mainly focused on the mechanisms of AA-induced nephropathy.
- Open Access
- 1 December 2017
- Published by Wolters Kluwer Health in Medicine
- Vol. 96 (49) , e9093
A rare case of methimazole-induced cholestatic jaundice in an elderly man of Asian ethnicity with hyperthyroidism
Methimazole is an antithyroid drug that is widely used for the treatment of hyperthyroidism. As an inhibitor of the enzyme thyroperoxidase, methimazole is generally well-tolerated. However, there have been increasing reports of methimazole-induced liver damage, although this effect of methimazole has been limited by the absence of objective diagnosis of the liver condition or the inappropriate use of the Naranjo scale. We present the case of an elderly man with hyperthyroidism, gastritis, and epilepsy who developed liver damage after administration of multiple drugs. Considering the low sensitivity of the Naranjo scale in detecting rare reactions associated with liver damage, we used the Roussel-Uclaf Causality Assessment Method scale, with a finding of cholestatic jaundice hepatitis induced by methimazole. The patient's liver enzyme levels improved after discontinuation of methimazole. Our case underlines the possible hepatoxicity associated with the use of methimazole. A review of the literature confirmed a selective hepatoxicity risk in individuals of Asian ethnicity, which has not been identified in Caucasian or Black populations. Physicians should be aware of the risk of hepatoxicity when prescribing oral methimazole to patients of Asian ethnicity.
- 1 December 2017
- Published by Wolters Kluwer Health in Medicine
- Vol. 96 (49) , e9093
Open AccessA rare case of methimazole-induced cholestatic jaundice in an elderly man of Asian ethnicity with hyperthyroidism
Methimazole is an antithyroid drug that is widely used for the treatment of hyperthyroidism. As an inhibitor of the enzyme thyroperoxidase, methimazole is generally well-tolerated. However, there have been increasing reports of methimazole-induced liver damage, although this effect of methimazole has been limited by the absence of objective diagnosis of the liver condition or the inappropriate use of the Naranjo scale. We present the case of an elderly man with hyperthyroidism, gastritis, and epilepsy who developed liver damage after administration of multiple drugs. Considering the low sensitivity of the Naranjo scale in detecting rare reactions associated with liver damage, we used the Roussel-Uclaf Causality Assessment Method scale, with a finding of cholestatic jaundice hepatitis induced by methimazole. The patient's liver enzyme levels improved after discontinuation of methimazole. Our case underlines the possible hepatoxicity associated with the use of methimazole. A review of the literature confirmed a selective hepatoxicity risk in individuals of Asian ethnicity, which has not been identified in Caucasian or Black populations. Physicians should be aware of the risk of hepatoxicity when prescribing oral methimazole to patients of Asian ethnicity.